Search

This article is a special section in the Drug & Alcohol Review journal dedicated to honoring the life and work of Jude Byrne, a prominent advocate, policy influencer, and researcher in the alcohol and drug field. Jude's impact was significant and wide-reaching, both locally and globally. The collection of papers in this special section covers various topics, including community-researcher partnerships, parent and family advocacy, equitable and ethical research, gendered stigma, healthcare access for women who use drugs, and the importance of peer knowledge and expertise in research and policy. Jude's legacy is one of challenging inequalities, centering the experiences of people who use drugs, and advocating for human rights. [Extracted from the article]

Feasibility of a DCR in the ACT would be enhanced through a focus on people experiencing multiple and complex needs and who are consuming a range of drugs by varied routes of administration. The stakeholders we interviewed believed that public drug use was low and decreasing over time, in part due to the dispersion of public housing stock across the ACT resulting in decentralised - and therefore less visible - drug use hotspots. Drug Consumption Rooms (DCR) have been established in various countries around the world since the 1980s; in 2019 there were in excess of 119 facilities operating in 13 countries [1]. In 1999, the Australian Capital Territory (ACT) Legislative Assembly passed the I Supervised Injecting Place Trial Act 1999 i , which outlined a plan for the trial of a facility in Civic, the central business district of Canberra. [Extracted from the article]

March marks the second anniversary of the passing of globally esteemed drug reform advocate Jude Byrne. Identifying unapologetically as a person who injects drugs for over 40 years, Jude's living experience drove her human rights perspectives on drug use, law and health. Whether it was a high-level committee on national HIV prevention or a small, locally led health initiative to encourage hepatitis C testing, Jude provided advocacy and leadership. [Extracted from the article]

Introduction and Aims: Take-home naloxone (THN) programs commenced in Australia in 2012 in the Australian Capital Territory and programs now operate in five Australian jurisdictions. The purpose of this paper is to record the progress of THN programs in Australia, to provide a resource for others wanting to start THN projects, and provide a tool for policy makers and others considering expansion of THN programs in this country and elsewhere.Design and Methods: Key stakeholders with principal responsibility for identified THN programs operating in Australia provided descriptions of program development, implementation and characteristics. Short summaries of known THN programs from each jurisdiction are provided along with a table detailing program characteristics and outcomes.Results: Data collected across current Australian THN programs suggest that to date over 2500 Australians at risk of overdose have been trained and provided naloxone. Evaluation data from four programs recorded 146 overdose reversals involving naloxone that was given by THN participants.Discussion and Conclusions: Peer drug user groups currently play a central role in the development, delivery and scale-up of THN in Australia. Health professionals who work with people who use illicit opioids are increasingly taking part as alcohol and other drug-related health agencies have recognised the opportunity for THN provision through interactions with their clients. Australia has made rapid progress in removing regulatory barriers to naloxone since the initiation of the first THN program in 2012. However, logistical and economic barriers remain and further work is needed to expand access to this life-saving medication. [ABSTRACT FROM AUTHOR]